In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles
Ex vivo autologous hematopoietic stem cell (HSC) gene therapy has provided new therapies for the treatment of hematological disorders. However, these therapies have several limitations owing to the manufacturing complexities and toxicity resulting from required conditioning regimens. Here, we develo...
Main Authors: | Shi, Dennis, Toyonaga, Sho, Anderson, Daniel G |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemical Engineering |
Format: | Article |
Language: | English |
Published: |
American Chemical Society
2024
|
Online Access: | https://hdl.handle.net/1721.1/156899 |
Similar Items
-
In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy
by: Guimarães, Pedro PG, et al.
Published: (2024) -
Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery
by: Alabi, Christopher A., et al.
Published: (2014) -
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21
by: Roy, A, et al.
Published: (2012) -
Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets
by: Milosevic, TV, et al.
Published: (2024) -
Targeted hematopoietic stem cell depletion through SCF-blockade
by: Chan, Yan Y., et al.
Published: (2024)